Milestone Pharmaceuticals Inc.
MIST
NASDAQ·Healthcare·Biotechnology·Mkt cap $149.4M
$1.20
▼ -0.83%
P/E
-2.16
Mkt Cap
$149.4M
52-Wk Range
$1.00–$3.06
52-Week Range
$1.00 - $3.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 31.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel calcium channel blocker mechanism with differentiated pharmacology
- Advanced clinical trial stage (Phase III) reducing development risk
- Strategic partnership with Ji Xing Pharmaceuticals for market expansion
- Focused pipeline addressing significant cardiovascular market opportunities
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Successful completion of Phase III clinical trials for PSVT indication
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-2.4% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying MIST right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.21 vs -$0.20 consensus (-7.7% surprise). Revenue of $559.0K vs $816.7K expected (-31.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.7%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$1.1M
$171.3K
$559.0K
Margins · last 8Q
Gross
94.3%
Profit
-5118.8%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Sep 4, 2026
vs Industry
How MIST stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.